Amedisys (NASDAQ:AMED – Get Rating) had its price objective lowered by investment analysts at Stephens from $122.00 to $106.00 in a research report issued on Friday, Stock Target Advisor reports. The firm presently has an “equal weight” rating on the health services provider’s stock. Stephens’ price target indicates a potential upside of 14.88% from the stock’s previous close.
A number of other brokerages have also recently commented on AMED. UBS Group lowered their target price on Amedisys to $88.00 in a report on Friday, November 4th. Barclays lowered their target price on Amedisys from $154.00 to $126.00 and set an “overweight” rating on the stock in a research note on Friday, October 28th. Royal Bank of Canada lowered their price objective on Amedisys from $165.00 to $139.00 and set an “outperform” rating on the stock in a report on Monday, October 31st. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Amedisys from $175.00 to $165.00 and set a “buy” rating on the stock in a research report on Monday, October 24th. Finally, Jefferies Financial Group restated a “buy” rating and set a $150.00 target price on shares of Amedisys in a research report on Wednesday, November 2nd. Two research analysts have rated the stock with a sell rating, five have given a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, Amedisys presently has an average rating of “Hold” and an average price target of $136.13.
Amedisys Stock Up 3.0 %
Shares of NASDAQ AMED traded up $2.70 during midday trading on Friday, reaching $92.27. 3,123 shares of the company’s stock traded hands, compared to its average volume of 608,468. The stock’s 50 day simple moving average is $102.38 and its 200-day simple moving average is $113.84. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.41. Amedisys has a one year low of $83.00 and a one year high of $185.23. The company has a market cap of $3.00 billion, a price-to-earnings ratio of 24.77, a P/E/G ratio of 2.08 and a beta of 0.99.
Amedisys (NASDAQ:AMED – Get Rating) last released its quarterly earnings data on Thursday, October 27th. The health services provider reported $1.15 earnings per share for the quarter, missing analysts’ consensus estimates of $1.22 by ($0.07). The company had revenue of $557.99 million for the quarter, compared to analysts’ expectations of $579.30 million. Amedisys had a net margin of 5.45% and a return on equity of 16.00%. The business’s quarterly revenue was up .8% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.53 EPS. On average, analysts predict that Amedisys will post 4.87 EPS for the current fiscal year.
Hedge Funds Weigh In On Amedisys
A number of large investors have recently bought and sold shares of AMED. First Horizon Advisors Inc. lifted its holdings in shares of Amedisys by 862.5% in the 2nd quarter. First Horizon Advisors Inc. now owns 385 shares of the health services provider’s stock worth $40,000 after purchasing an additional 345 shares during the last quarter. Neo Ivy Capital Management bought a new position in shares of Amedisys during the second quarter worth about $44,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Amedisys in the 1st quarter worth about $46,000. IFP Advisors Inc lifted its position in Amedisys by 331.1% in the 3rd quarter. IFP Advisors Inc now owns 569 shares of the health services provider’s stock valued at $47,000 after purchasing an additional 437 shares during the last quarter. Finally, Covestor Ltd grew its position in Amedisys by 88.9% in the 1st quarter. Covestor Ltd now owns 323 shares of the health services provider’s stock worth $56,000 after purchasing an additional 152 shares during the last quarter. Institutional investors own 93.36% of the company’s stock.
Amedisys Company Profile
Amedisys, Inc engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amedisys, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Amedisys wasn’t on the list.
While Amedisys currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
Read More: Stephens Lowers Amedisys (NASDAQ:AMED) Price Target to $106.00